Evidence map›Paper›PMID 33765049›Full record

ArticlePloS one2021

ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida.

Eduardo Oliveira, Amay Parikh, Arnaldo Lopez-Ruiz, Maria Carrilo, Joshua Goldberg, Martin Cearras, Khaled Fernainy, Sonja Andersen, Luis Mercado, Jian Guan and 10 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
76citing papers in PubMed, 3 pooled it
9.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

76 citing papers in PubMed, 3 syntheses or guidelines pooled it, 144 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

16 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 1 institution in 1 country.

Eduardo OliveiraDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.ORCID 0000-0002-2565-7709
Amay ParikhDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Arnaldo Lopez-RuizDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Maria CarriloDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Joshua GoldbergDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Martin CearrasDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Khaled FernainyDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Sonja AndersenDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Luis MercadoInternal Medicine Residency Program, AdventHealth Orlando, Orlando, Florida, United States of America.
Jian GuanInternal Medicine Residency Program, AdventHealth Orlando, Orlando, Florida, United States of America.
Hammad ZafarInternal Medicine Residency Program, AdventHealth Orlando, Orlando, Florida, United States of America.
Patricia LouzonPharmacy Department, AdventHealth Orlando, Orlando, Florida, United States of America.ORCID 0000-0001-8824-252X
Amy CarrPharmacy Department, AdventHealth Orlando, Orlando, Florida, United States of America.ORCID 0000-0002-5197-7132
Natasha BalochDivision of Critical Care - AdventHealth Medical Group, AdventHealth Orlando, Orlando, Florida, United States of America.
Richard PratleyResearch Institute, AdventHealth Orlando, Orlando, Florida, United States of America.
Scott SilverstryTransplant Institute, AdventHealth Orlando, Orlando, Florida, United States of America.
Vincent HsuDivision of Infectious Diseases, AdventHealth Orlando, Orlando, Florida, United States of America.
Jason SniffenDivision of Infectious Diseases, AdventHealth Orlando, Orlando, Florida, United States of America.
Victor HerreraDivision of Infectious Diseases, AdventHealth Orlando, Orlando, Florida, United States of America.
Neil FinklerAdventHealth Orlando Central Florida Division, Orlando, Florida, United States of America.
AdventHealth Orlando · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundObservational studies have consistently described poor clinical outcomes and increased ICU mortality in patients with severe coronavirus disease 2019 (COVID-19) who require mechanical ventilation (MV). Our study describes the clinical characteristics and outcomes of patients with severe COVID-19 admitted to ICU in the largest health care system in the state of Florida, United States.

methodsRetrospective cohort study of patients admitted to ICU due to severe COVID-19 in AdventHealth health system in Orlando, Florida from March 11th until May 18th, 2020. Patients were characterized based on demographics, baseline comorbidities, severity of illness, medical management including experimental therapies, laboratory markers and ventilator parameters. Major clinical outcomes analyzed at the end of the study period were: hospital and ICU length of stay, MV-related mortality and overall hospital mortality of ICU patients.

resultsOut of total of 1283 patients with COVID-19, 131 (10.2%) met criteria for ICU admission (median age: 61 years [interquartile range (IQR), 49.5-71.5]; 35.1% female). Common comorbidities were hypertension (84; 64.1%), and diabetes (54; 41.2%). Of the 131 ICU patients, 109 (83.2%) required MV and 9 (6.9%) received ECMO. Lower positive end expiratory pressure (PEEP) were observed in survivors [9.2 (7.7-10.4)] vs non-survivors [10 (9.1-12.9] p = 0.004]. Compared to non-survivors, survivors had a longer MV length of stay (LOS) [14 (IQR 8-22) vs 8.5 (IQR 5-10.8) p< 0.001], Hospital LOS [21 (IQR 13-31) vs 10 (7-1) p< 0.001] and ICU LOS [14 (IQR 7-24) vs 9.5 (IQR 6-11), p < 0.001]. The overall hospital mortality and MV-related mortality were 19.8% and 23.8% respectively. After exclusion of hospitalized patients, the hospital and MV-related mortality rates were 21.6% and 26.5% respectively.

conclusionsOur study demonstrates an important improvement in mortality of patients with severe COVID-19 who required ICU admission and MV in comparison to previous observational reports and emphasizes the importance of standard of care measures in the management of COVID-19.

Indexed as

Delivery of Health CareAdolescentAdultAgedComorbidityCOVID-19Extracorporeal Membrane OxygenationFemaleFloridaHospital MortalityHumansIntensive Care UnitsLength of StayMaleMiddle AgedRespiration, Artificial

Identifiers

PMID33765049
PMCPMC7993561
OpenAlexW3136171392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.